Logo image of ACOG

ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACOG - CA02074J5017 - Common Stock

5.72 USD
-0.1 (-1.72%)
Last: 1/16/2026, 8:00:00 PM
5.72 USD
0 (0%)
After Hours: 1/16/2026, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, ACOG scores 3 out of 10 in our fundamental rating. ACOG was compared to 528 industry peers in the Biotechnology industry. ACOG has a great financial health rating, but its profitability evaluates not so good. ACOG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ACOG had negative earnings in the past year.
  • ACOG had a negative operating cash flow in the past year.
  • ACOG had negative earnings in each of the past 5 years.
  • In the past 5 years ACOG always reported negative operating cash flow.
ACOG Yearly Net Income VS EBIT VS OCF VS FCFACOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • ACOG's Return On Assets of -42.06% is in line compared to the rest of the industry. ACOG outperforms 57.95% of its industry peers.
  • ACOG has a better Return On Equity (-57.42%) than 62.50% of its industry peers.
Industry RankSector Rank
ROA -42.06%
ROE -57.42%
ROIC N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG Yearly ROA, ROE, ROICACOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACOG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG Yearly Profit, Operating, Gross MarginsACOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ACOG has more shares outstanding
  • ACOG has a better debt/assets ratio than last year.
ACOG Yearly Shares OutstandingACOG Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACOG Yearly Total Debt VS Total AssetsACOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • ACOG has an Altman-Z score of 3.34. This indicates that ACOG is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.34, ACOG is in the better half of the industry, outperforming 68.94% of the companies in the same industry.
  • ACOG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.34
ROIC/WACCN/A
WACCN/A
ACOG Yearly LT Debt VS Equity VS FCFACOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

  • ACOG has a Current Ratio of 6.69. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.
  • ACOG's Current ratio of 6.69 is fine compared to the rest of the industry. ACOG outperforms 68.37% of its industry peers.
  • A Quick Ratio of 6.03 indicates that ACOG has no problem at all paying its short term obligations.
  • ACOG has a better Quick ratio (6.03) than 64.58% of its industry peers.
Industry RankSector Rank
Current Ratio 6.69
Quick Ratio 6.03
ACOG Yearly Current Assets VS Current LiabilitesACOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

  • ACOG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ACOG will show a very negative growth in Earnings Per Share. The EPS will decrease by -306.97% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1293.75%
EPS Next 2Y-306.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOG Yearly Revenue VS EstimatesACOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
ACOG Yearly EPS VS EstimatesACOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACOG. In the last year negative earnings were reported.
  • Also next year ACOG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG Price Earnings VS Forward Price EarningsACOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG Per share dataACOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as ACOG's earnings are expected to decrease with -306.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-306.97%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ACOG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALPHA COGNITION INC

NASDAQ:ACOG (1/16/2026, 8:00:00 PM)

After market: 5.72 0 (0%)

5.72

-0.1 (-1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners34.05%
Inst Owner ChangeN/A
Ins Owners9.57%
Ins Owner Change-5.15%
Market Cap124.35M
Revenue(TTM)7.43M
Net Income(TTM)-19.47M
Analysts82.86
Price Target18.36 (220.98%)
Short Float %0.85%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.4%
Min EPS beat(2)-24.95%
Max EPS beat(2)81.76%
EPS beat(4)2
Avg EPS beat(4)32.67%
Min EPS beat(4)-24.95%
Max EPS beat(4)81.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)11.14%
Min Revenue beat(2)-14.76%
Max Revenue beat(2)37.04%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)-5.88%
EPS NQ rev (3m)21.74%
EPS NY rev (1m)-1.36%
EPS NY rev (3m)22.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-46.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.74
P/FCF N/A
P/OCF N/A
P/B 3.67
P/tB 3.71
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.34
BVpS1.56
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.06%
ROE -57.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.69
Quick Ratio 6.03
Altman-Z 3.34
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)12.76%
Cap/Depr(5y)24.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-1293.75%
EPS Next 2Y-306.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.96%
OCF growth 3YN/A
OCF growth 5YN/A

ALPHA COGNITION INC / ACOG FAQ

Can you provide the ChartMill fundamental rating for ALPHA COGNITION INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACOG.


What is the valuation status of ALPHA COGNITION INC (ACOG) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALPHA COGNITION INC (ACOG). This can be considered as Overvalued.


Can you provide the profitability details for ALPHA COGNITION INC?

ALPHA COGNITION INC (ACOG) has a profitability rating of 1 / 10.


How financially healthy is ALPHA COGNITION INC?

The financial health rating of ALPHA COGNITION INC (ACOG) is 8 / 10.